Logo image of ALCLS.PA

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

EPA:ALCLS - FR0010425595 - Common Stock

2.48 EUR
+0.06 (+2.48%)
Last: 9/9/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALCLS scores 2 out of 10 in our fundamental rating. ALCLS was compared to 70 industry peers in the Biotechnology industry. ALCLS may be in some trouble as it scores bad on both profitability and health. ALCLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALCLS had negative earnings in the past year.
In the past year ALCLS has reported a negative cash flow from operations.
ALCLS had negative earnings in each of the past 5 years.
ALCLS had negative operating cash flow in 4 of the past 5 years.
ALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -28.30%, ALCLS perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
ALCLS has a Return On Equity (-103.16%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -28.3%
ROE -103.16%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ALCLS.PA Yearly ROA, ROE, ROICALCLS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALCLS has a Gross Margin (3.66%) which is in line with its industry peers.
ALCLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCLS.PA Yearly Profit, Operating, Gross MarginsALCLS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALCLS has more shares outstanding
ALCLS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALCLS has an improved debt to assets ratio.
ALCLS.PA Yearly Shares OutstandingALCLS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALCLS.PA Yearly Total Debt VS Total AssetsALCLS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ALCLS has an Altman-Z score of -0.71. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.
ALCLS has a Altman-Z score (-0.71) which is in line with its industry peers.
A Debt/Equity ratio of 0.91 indicates that ALCLS is somewhat dependend on debt financing.
ALCLS has a Debt to Equity ratio of 0.91. This is comparable to the rest of the industry: ALCLS outperforms 47.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z -0.71
ROIC/WACCN/A
WACC6%
ALCLS.PA Yearly LT Debt VS Equity VS FCFALCLS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.38 indicates that ALCLS should not have too much problems paying its short term obligations.
ALCLS has a worse Current ratio (1.38) than 65.71% of its industry peers.
ALCLS has a Quick Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
ALCLS has a worse Quick ratio (1.38) than 64.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.38
ALCLS.PA Yearly Current Assets VS Current LiabilitesALCLS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

ALCLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.89%, which is quite impressive.
ALCLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 236.67%.
Measured over the past years, ALCLS shows a quite strong growth in Revenue. The Revenue has been growing by 16.44% on average per year.
EPS 1Y (TTM)52.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)236.67%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%91.42%

3.2 Future

ALCLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -56.20% yearly.
The Revenue is expected to grow by 29.22% on average over the next years. This is a very strong growth
EPS Next Y-213.93%
EPS Next 2Y-50.24%
EPS Next 3Y-56.2%
EPS Next 5YN/A
Revenue Next Year-3.47%
Revenue Next 2Y26.88%
Revenue Next 3Y12.87%
Revenue Next 5Y29.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALCLS.PA Yearly Revenue VS EstimatesALCLS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
ALCLS.PA Yearly EPS VS EstimatesALCLS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCLS.PA Price Earnings VS Forward Price EarningsALCLS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCLS.PA Per share dataALCLS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

ALCLS's earnings are expected to decrease with -56.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.24%
EPS Next 3Y-56.2%

More info and screens

0

5. Dividend

5.1 Amount

ALCLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS

EPA:ALCLS (9/9/2025, 7:00:00 PM)

2.48

+0.06 (+2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/dmh
Earnings (Next)11-03 2025-11-03
Inst Owners18.59%
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap248.81M
Analysts84.62
Price Target6.63 (167.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.93%
Min EPS beat(2)4.37%
Max EPS beat(2)25.48%
EPS beat(4)4
Avg EPS beat(4)48.46%
Min EPS beat(4)4.37%
Max EPS beat(4)145.69%
EPS beat(8)7
Avg EPS beat(8)30.86%
EPS beat(12)9
Avg EPS beat(12)22.27%
EPS beat(16)12
Avg EPS beat(16)21.54%
Revenue beat(2)1
Avg Revenue beat(2)21.17%
Min Revenue beat(2)-20.05%
Max Revenue beat(2)62.39%
Revenue beat(4)3
Avg Revenue beat(4)64.94%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)161.56%
Revenue beat(8)5
Avg Revenue beat(8)33.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.88%
EPS NQ rev (3m)-0.18%
EPS NY rev (1m)6.32%
EPS NY rev (3m)6.32%
Revenue NQ rev (1m)-8.53%
Revenue NQ rev (3m)-43.42%
Revenue NY rev (1m)-4.93%
Revenue NY rev (3m)-40.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.12
P/FCF N/A
P/OCF N/A
P/B 3.01
P/tB 3.05
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.79
BVpS0.82
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.3%
ROE -103.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.66%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.04%
Cap/Sales 3.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.38
Altman-Z -0.71
F-Score3
WACC6%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-213.93%
EPS Next 2Y-50.24%
EPS Next 3Y-56.2%
EPS Next 5YN/A
Revenue 1Y (TTM)236.67%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%91.42%
Revenue Next Year-3.47%
Revenue Next 2Y26.88%
Revenue Next 3Y12.87%
Revenue Next 5Y29.22%
EBIT growth 1Y46.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.14%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y51.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.32%
OCF growth 3YN/A
OCF growth 5YN/A